TYROBP and neoplasm: In this experiment, we established two groups of increasing doses (2 × 105 and 8 × 105 SS1 KIRS2/Dap12-BB CAR-T cells) and found that although pancreatic adenocarcinoma relapsed by day 98 in the low-dose group, the tumor did not relapse for more than 100 days in the high-dose group (Figures 3E and 3F).